0001193125-21-055675.txt : 20210225 0001193125-21-055675.hdr.sgml : 20210225 20210225070131 ACCESSION NUMBER: 0001193125-21-055675 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20210224 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20210225 DATE AS OF CHANGE: 20210225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vanda Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001347178 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 030491827 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34186 FILM NUMBER: 21676355 BUSINESS ADDRESS: STREET 1: 2200 PENNSYLVANIA AVE NW STREET 2: SUITE 300E CITY: WASHINGTON STATE: DC ZIP: 20037 BUSINESS PHONE: 202-734-3400 MAIL ADDRESS: STREET 1: 2200 PENNSYLVANIA AVE NW STREET 2: SUITE 300E CITY: WASHINGTON STATE: DC ZIP: 20037 8-K 1 d75499d8k.htm 8-K 8-K
false 0001347178 0001347178 2021-02-24 2021-02-24

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 25, 2021 (February 24, 2021)

 

 

VANDA PHARMACEUTICALS INC.

(Exact name of Registrant as specified in its charter)

 

 

Delaware

(State or other jurisdiction of incorporation)

 

001-34186   03-0491827
(Commission File No.)   (IRS Employer Identification No.)

2200 Pennsylvania Avenue NW

Suite 300E

Washington, DC 20037

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (202) 734-3400

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   VNDA   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e)    On February 24, 2021, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of Vanda Pharmaceuticals Inc. (the “Company”) awarded 2020 annual bonuses and approved 2021 annual base salaries and 2021 bonus target amounts for the Company’s named executive officers. Prior to approving the foregoing, the Compensation Committee reviewed an analysis of the Company’s executive compensation compared to the Company’s peer group conducted by Willis Towers Watson, a compensation consultant engaged by the Compensation Committee.

The Compensation Committee awarded bonuses for performance for the twelve-month period ended December 31, 2020, in the amounts set forth opposite the names of the executive officers listed below.

 

Name

   

Position

   

2020 Bonus

  
Mihael Polymeropoulos, M.D.    President and Chief Executive Officer    $ 656,687  
Kevin Moran    Senior Vice President, Chief Financial Officer and Treasurer    $ 200,000  
Timothy Williams    Senior Vice President, General Counsel and Secretary    $ 200,000  
Gunther Birznieks    Senior Vice President, Business Development    $ 200,000  

The Compensation Committee approved 2021 annual base salaries and 2021 bonus target amounts for the twelve-month period ending December 31, 2021 in the amounts set forth opposite the names of the executive officers listed below.

 

Name

   

Position

   

2021 Base Salary

     

2021 Target Bonus

  
Mihael Polymeropoulos, M.D.    President and Chief Executive Officer    $ 769,000        80 % 
Kevin Moran    Senior Vice President, Chief Financial Officer and Treasurer    $ 402,000        45 % 
Timothy Williams    Senior Vice President, General Counsel and Secretary    $ 440,000        45 % 
Gunther Birznieks    Senior Vice President, Business Development    $ 434,000        45 % 

In addition, the Compensation Committee granted (i) options to purchase shares of the Company’s common stock at an exercise price equal to $20.28 per share, the closing price of the Company’s common stock on The Nasdaq Global Market on February 24, 2021, and (ii) restricted stock unit (“RSU”) awards under the Company’s Amended and Restated 2016 Equity Incentive Plan to its named executive officers in the amounts set forth opposite the names of the executive officers listed below. The options vest with respect to 25% of the underlying shares on February 24, 2022, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter. The RSUs for all named executive officers will vest in four equal annual installments beginning on March 1, 2022.

Name

   

Position

    Number of Shares
Underlying Option
Grant		     

Number of Shares

Underlying RSU Award

  
Mihael Polymeropoulos, M.D.    President and Chief Executive Officer      275,000        115,000  
Kevin Moran    Senior Vice President, Chief Financial Officer and Treasurer      77,500        32,700  
Timothy Williams    Senior Vice President, General Counsel and Secretary      77,500        32,700  
Gunther Birznieks    Senior Vice President, Business Development      77,500        32,700  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: February 25, 2021     VANDA PHARMACEUTICALS INC.
    By:  

/s/ Timothy Williams

    Name:   Timothy Williams
    Title:   Senior Vice President, General Counsel and Secretary
 EX-101.SCH 2 vnda-20210224.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 vnda-20210224_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 vnda-20210224_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 d75499d8k_htm.xml IDEA: XBRL DOCUMENT 0001347178 2021-02-24 2021-02-24 false 0001347178 8-K 2021-02-24 VANDA PHARMACEUTICALS INC. DE 001-34186 03-0491827 2200 Pennsylvania Avenue NW Suite 300E Washington DC 20037 (202) 734-3400 false false false false Common Stock, par value $0.001 per share VNDA NASDAQ false XML 6 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information
Feb. 24, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001347178
Document Type 8-K
Document Period End Date Feb. 24, 2021
Entity Registrant Name VANDA PHARMACEUTICALS INC.
Entity Incorporation State Country Code DE
Entity File Number 001-34186
Entity Tax Identification Number 03-0491827
Entity Address, Address Line One 2200 Pennsylvania Avenue NW
Entity Address, Address Line Two Suite 300E
Entity Address, City or Town Washington
Entity Address, State or Province DC
Entity Address, Postal Zip Code 20037
City Area Code (202)
Local Phone Number 734-3400
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol VNDA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d75499d8k.htm vnda-20210224.xsd vnda-20210224_lab.xml vnda-20210224_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d75499d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d75499d8k.htm" ] }, "labelLink": { "local": [ "vnda-20210224_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "vnda-20210224_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "vnda-20210224.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "vnda", "nsuri": "http://www.vandapharmaceuticals.com/20210224", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d75499d8k.htm", "contextRef": "duration_2021-02-24_to_2021-02-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d75499d8k.htm", "contextRef": "duration_2021-02-24_to_2021-02-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vandapharmaceuticals.com//20210224/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001193125-21-055675-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-055675-xbrl.zip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end